Parabilis Medicines

📅 Upcoming

🕒 Recent(90d)

News

• With tech backing, AI biotechs force biopharma into ‘fail-fast’ drug development
  AI is quickly becoming a central force in drug development, from powering pharma engines to permanently rewiring the capital markets.
  biospace · 3d ago
• 2026 Q2 Job Market Report: Job postings keep rising as fewer companies cut employees
  Job postings increase and competition dips, according to BioSpace data.
  biospace · 8d ago
• BlossomHill, Latigo outshine IPO expectations with oversubscribed debuts
  Two growing biotechs blasted through their IPO expectations Friday, with Blossom Hill Therapeutics and Latigo Biotherapeutics each raising at least 30% more than expected in their stock market debuts.
  fiercebiotech · 8d ago
• With $263M, LifeMine unearths a new drug for organ transplants
  Led by serial biotech entrepreneur Greg Verdine, the startup mined fungi genomes to find a safer alternative to the drugs widely used to prevent the body from rejecting transplanted organs.
  biopharma_dive · 9d ago
• Braveheart charges past expectations with $382.5M IPO to fund cardio drug from Hengrui
  Braveheart Bio has overcome its own IPO expectations, rallying $382.5 million in an upsized listing to fund its cardiovascular ambitions.
  fiercebiotech · 9d ago
• ‘Greg, you’ve got to bring back this platform’: How LifeMine won over Gates and Bezos for $188M series E
  A little over a year ago, LifeMine Therapeutics laid off staff and put its fungus-based platform on ice to focus its dwindling resources on its lead asset. Now, the Massachusetts biotech is shaking…
  fiercebiotech · 10d ago
• Apnimed’s IPO dream comes true with upsized $192M IPO to fund sleep apnea pill launch
  Apnimed has raised $192 million for its upsized IPO, with the proceeds earmarked to fund the launch of its sleep apnea pill.
  fiercebiotech · 15d ago
• Scribe reels in nearly $129M in rare early-stage IPO for a gene editing biotech
  Jennifer Doudna–founded Scribe Therapeutics intends to use the proceeds from the public offering—the first for a gene editing outfit in over two years—to support development of its epigenetic silen…
  biospace · 22d ago
• Scribe secures $129M in a rare gene editing IPO
  The startup is the first gene editing company to price an IPO in more than two years, though it banked far less than most other biotechs that have gone public in 2026.
  biopharma_dive · 22d ago
• Scribe records upsized $129M IPO to bankroll lipid-lowering genetic meds
  In vivo gene editing outfit Scribe Therapeutics has priced its IPO at $128.7 million, surpassing the $96 million goal set out earlier this week.
  fiercebiotech · 22d ago